Search research articles
Contact Us
Filters
Showing results (131-140 of 227) with videos related to
Page
of 23
Sort By:
Translational Oncology
|
August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative
Oluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
Cancer Chemotherapy and Pharmacology
|
May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions
Lawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A Massett, Grace Mishkin, Larry Rubinstein, et al.
JCO Clinical Cancer Informatics
|
January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug Development
Joyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2013
Developing standards for breakthrough therapy designation in oncology
Sandra J Horning, Daniel A Haber, Wendy K D Selig, et al.
The Oncologist
|
March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
Shivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Oncotarget
|
February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore, S Percy Ivy, Frank M Balis, et al.
Page
of 23
Search research articles
Search
Showing results (131-140 of 227) with videos related to
Sort By:
Page
of 23
Translational Oncology
|
August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative
Oluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
Cancer Chemotherapy and Pharmacology
|
May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions
Lawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A Massett, Grace Mishkin, Larry Rubinstein, et al.
JCO Clinical Cancer Informatics
|
January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug Development
Joyce F Liu, Jung-Min Lee, Ellie Strock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2013
Developing standards for breakthrough therapy designation in oncology
Sandra J Horning, Daniel A Haber, Wendy K D Selig, et al.
The Oncologist
|
March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
Shivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Oncotarget
|
February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore, S Percy Ivy, Frank M Balis, et al.
Page
of 23